Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

GRECCO-19, 2020
RCTcolchicinestandard of careCOVID 19 hospitalizedsome concern
55/50 suggested
  • suggested 89 % decrease in clinical deterioration with a moderate degree of certainty due to some concern in risk of bias
Salehzadeh, 2020
RCTcolchicineplaceboCOVID 19 hospitalizedsome concern
50/50 inconclusive
    Comparing two groups showed significantly different only in the duration of hospitalized (P<0.05). Although in colchicine group dyspnea was improved more rapid than the placebo group, but it was not meaningful.

    COVID-19 mild to moderate meta-analysis

    Lopes MIF, 2020
    RCTcolchicineplaceboCOVID-19 mild to moderatehigh
    17/18 no results

      PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
      Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).